spacer
home > ict > spring 2018 > imaging innovations
PUBLICATIONS
International Clinical Trials

Imaging Innovations

In every clinical trial, data rules. In trials for treatments of solid cancerous tumours, much of that critical data relates to the size, type, and appearance of new lesions, whether used as eligibility criteria or as safety or efficacy endpoints. The importance of having clean, accurate measures and objective interpretations of those measures to the success of an oncology trial cannot be overstated.

Ensuring the validity of imaging data points in oncology trials is particularly challenging due to the complexity and variability in acquiring and assessing images. Protocols must set forth the choice of imaging modality, the image acquisition parameters, and the specific protocol for the IV contrast or oral contrast. This will enable the application of more than 10 different assessment criteria.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Sophie Winandy is Product Manager at ERT and has more than 10 years of experience working closely with clinical trial sponsors and CROs to identify and implement optimal imaging approaches that accelerate the development of new medical products. Drawing on her training as a Registered Technologist, Magnetic Resonance Imaging, Sophie helped to develop the imaging solutions employed by researchers across hundreds of clinical trials during her tenure at Biomedical Systems (acquired by ERT in 2017).
spacer
Sophie Winandy
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Staffordshire company Woolcool wins 2018 Queen’s Award for Innovation

The world is crying out for genuinely sustainable alternatives to manmade plastic packaging, so the winning of a Queen’s Award for Enterprise in Innovation by Staffordshire company Woolcool demonstrates the very real credibility of using a natural, renewable packaging resource – sheeps wool. First conceived by founder and CEO Angela Morris in 2001, Woolcool is a superior insulated packaging solution for the transportation of temperature-sensitive goods for the food and pharmaceutical sectors.
More info >>

White Papers

Mouse Models for Evaluation of Vaccines and Therapeutics Against Staphylococcal Infections

IBT Bioservices

Introduction Staphylococcus aureus (SA) is a ubiquitous, formidable Gram-positive pathogen associated with skin and soft tissue, as well as lifethreatening systemic infections. SA is a leading cause of hospital- and community-associated infections worldwide, affecting humans and animals. The wide range of pathologies reflects the diverse abilities of this microbe to escape the innate and adaptive immune response using virulence factors. Since its first emergence in the 1960s methicillin-resistant SA (MRSA) has become endemic in hospitals and healthcare settings worldwide. In the 1990s, community associated MRSA strains (CA-MRSA) emerged, and are spreading worldwide posing a major global challenge.
More info >>

 
Industry Events

Nordic Life Science Days 2018

10-12 September 2018, Stockholm Waterfront Conference Center, Sweden

The Nordic way of doing life science business NLSDays offers networking and knowledge for anyone interested in the Nordic life science, biotechnologies, pharmaceuticals, medical devices and e-health business. We offer plenty of opportunities to connect.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement